BAXTER INTL INC shareholders Q3 2020

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2020
NameSharesValueWeighting ↓
Eudaimonia Partners, LLC 14,421$1,160,0000.30%
Endurant Capital Management LP 12,575$1,011,0000.30%
CIM INVESTMENT MANAGEMENT INC 9,757$785,0000.30%
WALLED LAKE PLANNING & WEALTH MANAGEMENT, LLC 4,556$366,0000.30%
Capital International Investors 11,957,557$961,553,0000.30%
TWIN CAPITAL MANAGEMENT INC 40,442$3,252,0000.29%
Engineers Gate Manager LP 77,501$6,233,0000.29%
PGGM Investments 693,247$55,751,0000.29%
INSPIRION WEALTH ADVISORS, LLC 10,537$847,0000.29%
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 4,039,881$324,887,0000.29%
EXENCIAL WEALTH ADVISORS, LLC 67,322$5,414,0000.29%
Sargent Investment Group, LLC 9,702$780,0000.28%
Cubist Systematic Strategies, LLC 237,409$19,092,0000.28%
FORT PITT CAPITAL GROUP, LLC 63,103$5,075,0000.28%
AMERIPRISE FINANCIAL INC 8,647,450$695,423,0000.28%
Total Clarity Wealth Management, Inc. 4,027$324,0000.28%
Hanson & Doremus Investment Management 11,687$940,0000.28%
GATEWAY INVESTMENT ADVISERS LLC 293,414$23,596,0000.27%
SEVEN EIGHT CAPITAL, LP 15,500$1,247,0000.27%
TWO SIGMA INVESTMENTS, LP 944,964$75,994,0000.27%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.